Edwards Boosted by CMS TAVR Coverage Update

CMS Finalizes Updated TAVR National Coverage Determination

CMS published a finalized, updated transcatheter aortic valve replacement (TAVR) national coverage determination on Friday, aligning closely with the language of its June proposal. The final decision re‑affirms support for TAVR in asymptomatic aortic stenosis patients, a key factor that prompted the reopening of the coverage determination.

Market Context

The TAVR market exceeds $7 billion globally. It accounts for roughly 75 % of Edwards Lifesciences’ revenue and about 5.5 % of Medtronic’s revenue, underscoring the significance of the coverage policy for both firms.

New Coverage Analysis for Aortic Regurgitation

CMS announced a concurrent national coverage analysis for TAVR devices intended to treat aortic regurgitation. The analysis will consider devices such as Edwards’ clinical‑stage J‑Valve and the privately held, FDA‑approved JenaValve, with an expected completion date of June 8 2027.

Heart‑Team and Clinical Process Requirements

The final document maintains the heart‑team model, explicitly stating that both cardiac surgeons and interventional cardiologists must contribute to patient evaluation. While medical records may now be used asynchronously to assess patient suitability, an in‑person evaluation remains mandatory, and the cardiac surgeon continues to play a role.

Operating‑Room Staffing Changes

CMS now requires only one TAVR operator to be present in the operating room during a procedure, provided the site has cardiac‑surgery backup. Dropping the requirement for a surgeon to be physically present is highlighted as a scheduling‑efficiency benefit.

Volume Standards for Operators

Operator volume thresholds remain unchanged: annually, a provider must perform at least 20 total transcatheter cardiac valve procedures, of which 15 must be TAVR; alternatively, over a two‑year period, the threshold is 40 total procedures with at least 30 TAVR cases.

Medicare Evidence‑Development Requirement

Medicare eliminated the coverage‑with‑evidence‑development (CED) requirement for all severe aortic stenosis patients, except for the newly supported asymptomatic severe aortic stenosis cohort.

Analyst Perspective

Stifel analysts consider the finalized update a net positive for the overall TAVR market and specifically for Edwards Lifesciences. They note that the change supports Edwards’ long‑range revenue growth outlook of more than 10 % and aligns with the company’s pipeline innovations and favorable competitive dynamics.